BridgeMD
Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study
EU CTIS ID: 2024-515328-35-00
What this study is testing
Describe the characteristics of endothelial EVs and their temporal evolution before and after treatment with CAR-T cells according to ICANS grade.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient over 18 years old
- Patients for whom CAR-T treatment of their disease is indicated
- Patient affiliated to or entitled under a social security scheme
- Patient has received informed consent to participate in the study and has co-signed a consent form with the investigator.
You likely can't join if
- Pregnant or breast-feeding woman
- Patient unable to understand informed consent
- Patient deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice, family habilitation).
- Contraindication to MRI
- Contraindication to contrast product
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.